Syndax Pharmaceuticals Q3 2025 Earnings Preview

* Syndax Pharmaceuticals (SNDX [https://seekingalpha.com/symbol/SNDX]) is scheduled to announce Q3 earnings results on Monday, November 3rd, after market close.
The consensus EPS Estimate is -$0.71 [https://seekingalpha.com/symbol/SNDX/earnings/estimates] (+27.6% Y/Y) and the consensus Revenue Estimate is $47.97M (+283.8% Y/Y).Over the last 3 months, EPS estimates have seen 10 upward revisions [https://seekingalpha.com/symbol/SNDX/earnings/revisions] and 0 downward. Revenue estimates have seen 10 upward revisions and 0 downward.

MORE ON SYNDAX PHARMACEUTICALS

* Syndax Expands Revuforj Approval, Buy [https://seekingalpha.com/article/4833527-syndax-expands-revuforj-approval]
* Syndax Pharmaceuticals, Inc. (SNDX) Discusses FDA Approval of Revuforj for Relapsed or Refractory NPM1 Mutated Acute Myeloid Leukemia Transcript [https://seekingalpha.com/article/4833320-syndax-pharmaceuticals-inc-sndx-discusses-fda-approval-of-revuforj-for-relapsed-or-refractory]
* Syndax Pharmaceuticals, Inc. (SNDX) Discusses FDA Approval of Revuforj for Relapsed or Refractory NPM1 Mutated Acute Myeloid Leukemia - Slideshow [https://seekingalpha.com/article/4833321-syndax-pharmaceuticals-inc-sndx-discusses-fda-approval-of-revuforj-for-relapsed-or-refractory]
* Syndax gains additional indication for Revuforj in acute myeloid leukemia [https://seekingalpha.com/news/4508347-syndax-gains-additional-indication-revuforj-acute-myeloid-leukemia]
* Syndax resumed with Buy at Stifel on newly launched drugs [https://seekingalpha.com/news/4493767-syndax-stock-resumed-buy-stifel]